These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32976493)

  • 41. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
    Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
    Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM; Schriever CA; Badowski ME
    Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
    AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
    Rizzardini G; Gori A; Miralles C; Olalla J; Molina JM; Raffi F; Kumar P; Antinori A; Ramgopal M; Stellbrink HJ; Das M; Chu H; Ram R; Garner W; Shao Y; Chuck SK; Piontkowsky D; Haubrich RH
    AIDS; 2019 Aug; 33(10):1583-1593. PubMed ID: 31305329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France.
    Jacomet C; Allavena C; Peyrol F; Pereira B; Joubert LM; Bagheri H; Cotte L; Garaffo R; Gerbaud L; Dellamonica P
    PLoS One; 2015; 10(2):e0117214. PubMed ID: 25658627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
    Ba S; Raugi DN; Smith RA; Sall F; Faye K; Hawes SE; Sow PS; Seydi M; Gottlieb GS;
    Clin Infect Dis; 2018 Oct; 67(10):1588-1594. PubMed ID: 29672676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
    Rotzinger A; Locatelli I; Bugnon O; Fayet Mello A; Parienti JJ; Cavassini M; Schneider MP
    HIV Med; 2016 May; 17(5):390-6. PubMed ID: 26688004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 50. Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen.
    Engsig FN; Gerstoft J; Helleberg M; Nielsen LN; Kronborg G; Mathiesen LR; Obel N
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):407-13. PubMed ID: 24984188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
    Rokx C; Verbon A; Rijnders BJ
    HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
    Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
    Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
    Sutton SS; Magagnoli J; Hardin JW
    Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Gagliardini R; Bandera A; Zaccarelli M; Sterrantino G; Latini A; D'Avino A; Lapadula G; Antinori A; Cauda R; De Luca A; Gori A; Di Giambenedetto S; Fabbiani M
    Antivir Ther; 2018; 23(2):139-148. PubMed ID: 28799920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
    Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
    J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
    Allavena C; Volteau C; André-Garnier E; Guimard T; Hall N; Khatchatourian L; Morrier M; Billaud E; Rodallec A; Reliquet V; Jovelin T; Le Guen L; Perré P; Grégoire M; Raffi F
    Med Mal Infect; 2019 Oct; 49(7):505-510. PubMed ID: 30583867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection.
    Young J; Smith C; Teira R; Reiss P; Jarrín Vera I; Crane H; Miro JM; D'Arminio Monforte A; Saag M; Zangerle R; Bucher HC;
    HIV Med; 2018 Feb; 19(2):132-142. PubMed ID: 29110395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.